Futibatinib

CHEMBL3701238 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

418.4 g/mol

LogP

2.0

Phase

4

This oral medication selectively and irreversibly inhibits FGFR1-4, receptors that drive the growth of certain cancers when mutated or overactive. It is used to treat cholangiocarcinoma with FGFR2 gene rearrangements and is being studied in bladder and breast cancers with FGFR alterations.

Masse moléculaire

418,4000 g/mol

LogP

2,00

TPSA

108,00 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

C=CC(=O)N1CC[C@H](n2nc(C#Cc3cc(OC)cc(OC)c3)c3c(N)ncnc32)C1

InChI

InChI=1S/C22H22N6O3/c1-4-19(29)27-8-7-15(12-27)28-22-20(21(23)24-13-25-22)18(26-28)6-5-14-9-16(30-2)11-17(10-14)31-3/h4,9-11,13,15H,1,7-8,12H2,2-3H3,(H2,23,24,25)/t15-/m0/s1

Molecular Formula

C22H22N6O3

HBD / HBA

1 / 7

Liaisons Rotatives

6

Atomes Lourds

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This oral medication selectively and irreversibly inhibits FGFR1-4, receptors that drive the growth of certain cancers when mutated or overactive. It is used to treat cholangiocarcinoma with FGFR2 gene rearrangements and is being studied in bladder and breast cancers with FGFR alterations.

Yes, Futibatinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3701238. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 71621331. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Futibatinib sur PillFYI

Structure

Données Clés

Formule: C22H22N6O3
Synonymes: 1

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.